澳大利亚治疗商品管理局（TGA）近日发布通告称，制药公司Viatris Inc.已向其通报，由于美国供应链出现持续限制，旗下两种规格的胰酶补充剂——Creon 25,000单位胶囊和Creon 35,000单位胶囊——的供应短缺状况预计将延续至2027年1月31日。
这一供应中断源于美国的生产制约因素，直接影响了对澳大利亚市场的供货能力。TGA表示正在与Viatris保持密切沟通，并积极评估该情况对当地患者获取必需药物可能产生的影响。管理局建议医疗专业人员和患者关注官方渠道发布的最新信息，以妥善管理治疗计划。
目前，Viatris方面尚未披露造成美国供应限制的具体原因。此次长期的供应预警凸显了全球药品供应链的脆弱性，以及关键药物生产环节出现问题可能对依赖进口的市场造成的持续性挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.